Nisha Poddar
-
Zepto Delays IPO After Lukewarm MF Response, Pivots To Rs 1,000 Crore Fundraise: Sources
Zepto plans to update its financials and then go back to market to launch its public issue, persons privy to the development said.
-
Delhivery CEO Explains How They Tackle The Threat From In-House Logistics
In an exclusive interview with NDTV Profit, Sahil Barua said nearly 100% of freight contracts are fuel-cost protected, ruling out any long-term hit to margins from elevated crude oil prices.
-
Nifty Braces For 23,000 Test As AI Jitters, Iran War-Led Energy Shock Rattles D-Street: Manishi Raychaudhari
Emmer Capital's Raychaudhari outlined the current complex macroeconomic environment where global tech jitters, energy price spikes, and domestic inflation risks are converging to test investor resilience.
-
Manipal Hospital IPO 'Just An Event'; Temasek Bullish On Healthcare Run: Ravi Lambah
Temasek's Lambah noted that investment momentum remains strictly on track, with plans to deploy approximately $10 billion in India
-
Reliance Industries Promoters Raise Stake to 50% After Rs 9,000 Crore Creeping Acquisition
Promoter holding rose from 49.52% in March to 50% at the end of June after purchases during the first quarter.
-
Biocon's Shaw Reckons Rivals' China Reliance Gives It the Edge in GLP-1 Race
In an exclusive interview to NDTV Profit, Biocon founder, Kiran Mazumdar-Shaw, also said that insulin "will never go away" and defended company's low-margin bet.
-
Biocon's Shaw Pitches DNA-Based Data Centres as Answer to AI's Energy Problem
In an exclusive interview to NDTV Profit, Kiran Mazumdar-Shaw says biology, not silicon, could solve the data centre crunch.
-
Syngene 'Lost Its Way' But Kiran Mazumdar-Shaw Promises Turnaround by Next Fiscal
In an exclusive interview to NDTV Profit, Biocon founder says the CDMO arm strayed from its core strength but is now being rebuilt.
-
Novo Nordisk Launches Once-Weekly Insulin In India; Promises Competitive Pricing, Wider Access
Awiqli cuts basal insulin dosing from seven injections a week to one. Novo Nordisk India MD Vikrant Shrotriya discusses price, access and growth.
-
Tata Trusts Reject Allegations Over 1989 Tata Sons Share Transfer, Threaten Legal Action
The statement was issued in response to a complaint reportedly made to the Charity Commissioner regarding the transfer of Tata Sons shares that took place over three decades ago.
-
Aditya Birla Group Emerges Front Runner To Buy Shell's Sprng Energy For $1.7 Billion
As part of the process, the Aditya Birla Group will conduct due diligence over the next three to four weeks before deciding on a final agreement.
-
JSW Steel Vs Tata Steel: Two Very Different Bets On India's Steel Future
The divergence in strategy comes as both companies accelerate expansion plans amid expectations that India's steel demand will continue to outpace global markets
-
Tata Trusts Says Maharashtra Law Doesn't Affect Lifetime Trustees Appointed Before September 2025
The Bombay High Court has already disposed the petition that sought a stay on the May 16 meeting, Tata Trusts said.
-
Tata Trusts Board Meeting: Plea In Bombay High Court Seeks To Halt Meeting Over Trustee Rules
Governance issues have intensified in recent months at Tata Trusts following objections related to reappointment procedures and the validity of resolutions passed by certain trusts.
-
War Cost Pressures Aside, Ather Energy Looking At Profitibility Soon, Says CEO
While he noted the geopolitical situation has "changed the picture" and added more time to the trajectory, he remains bullish on the underlying business model.
